Examining CONSUN PHARMA (01681)'s Long-Term Value: The Nephrology Leader Continues to Lead the Way, with Diversified Innovation Strengthening Its Growth Foundation

Title context: Examining CONSUN PHARMA (01681)'s Long-Term Value: The Nephrology Leader Continues to Lead the Way, with Diversified Innovation Strengthening Its Growth Foundation Text: Since 2026, the Hong Kong pharmaceutical sector has continued its volatile adjustment pattern, and assets with certain profitability and dividend-paying capacity have increasingly gained market favor. As a leading enterprise in China's nephrology field, CONSUN PHARMA (01681), against the backdrop of double-digit growth in its own performance and significantly undervalued valuation, continues to send positive signals of long-term development to the market through a "combination punch" of high dividends and share buybacks. The interim financial report shows that CONSUN PHARMA achieved revenue of RMB 1.785 billion in the first half, a year-on-year increase of 13.8%; net profit attributable to shareholders of RMB 595 million, a year-on-year increase of 19.5%; and net operating cash flow of RMB 781 million, a sharp year-on-year increase of 58.6%, demonstrating solid profit quality. It can be observed that the company's profit growth rate outpaced its revenue growth rate during the period, which is particularly rare against the backdrop of an overall pressured industry. During the period, the company's gross profit reached RMB 1.452 billion, a year-on-year increase of 20.1%; the gross profit margin jumped from 77.1% in the same period last year to 81.4%. The improvement in gross profit margin stems from optimized supply chain management, improved production and operational efficiency, and declining procurement prices for core raw materials. While revenue grew, the company's cost control capabilities also strengthened simultaneously, and economies of scale are continuously being released. Compared horizontally with major listed traditional Chinese medicine companies in the Hong Kong and A-share markets, CONSUN PHARMA's growth quality stands out notably. Against the backdrop of the Hong Kong traditional Chinese medicine sector being under overall pressure, with multiple leading enterprises seeing both revenue and profit decline, CONSUN PHARMA became a rare "dual-growth" target in the industry with a 13.8% revenue growth rate and a 19.5% profit growth rate. More notably, CONSUN PHARMA's sales gross profit margin and net profit margin levels are significantly higher than the industry average, further highlighting its industry-leading profitability advantage. Based on solid fundamentals and ample cash flow, CONSUN PHARMA continues its high dividend payout, with an interim dividend of HK$0.38 per share, fully reflecting its confidence in future development. More noteworthy is that the company issued a voluntary announcement on May 27, clearly stating it would repurchase no more than HK$200 million worth of shares before December 31, 2026. After the interim results were released, the company has restarted buybacks, with a cumulative repurchase of 1.255 million shares as of September 17, further demonstrating management's high recognition of the company's intrinsic value and ample confidence in future growth. By business segment, the nephrology series products achieved sales of RMB 1.335 billion in the first half, a year-on-year increase of 18.1%, continuing to maintain a leading position in the market. The core product Uremic Clearance Granules is the first modern Chinese patent medicine for nephrology in China to pass evidence-based medical research, and has ranked first in the nephrology Chinese patent medicine market for many consecutive years, with definite clinical efficacy, continuing to lead the market. In terms of market space, the number of existing CKD stage 3-4 patients in China exceeds 20 million, and Uremic Clearance Granules still has enormous market penetration potential. At the results conference, the company introduced that since the centralized procurement landed in 2023, Uremic Clearance Granules have continued to increase in volume. In addition to the nephrology foundation, diversified business segments are also contributing incremental growth. Women's and children's medications generated revenue of RMB 187 million in the first half, a year-on-year increase of 9.1%. The core product Yuanlikang Iron Dextran Oral Solution is the only oral liquid iron supplement included in the National Essential Medicines List and the Medical Insurance Catalog, with market share steadily increasing. The hepatobiliary series products showed explosive growth, with first-half revenue surging 233.7% year-on-year. In medical imaging contrast agents, Gadoteric Acid Meglumine Injection was approved for marketing in August, and Octafluoropropane Lipid Microspheres and Gadoxetic Acid Disodium Injection are expected to be launched successively within the next six months. If the first-half performance reflects the company's current operational strength, then a series of strategic layouts point to a more long-term future. During the year, CONSUN PHARMA advanced simultaneously in three dimensionsindustrial chain extension, overseas expansion, and innovative R&Dbuilding a competitive moat. In terms of industrial chain layout, the company strategically invested RMB 191 million in Shanghai Huamao Pharmaceutical in June, acquiring a 30% stake. Shanghai Huamao has deep technical accumulation in synthetic biology, precision fermentation, and dialysis API R&D and production, highly compatible with the company's core businesses such as nephrology and women's and children's health, which will help the company reduce supply chain costs and ensure the stability of core raw material supply. This approach of controlling key nodes in the industrial chain from the source has significant strategic foresight at a time when supply chain fluctuations in the pharmaceutical industry are intensifying. In overseas markets, the company steadily advances its product expansion strategy, laying the foundation for subsequent global volume growth. Among these, Uremic Clearance Granules has initiated modern botanical drug registration in Indonesia, Vietnam, and Thailand, and has now successfully entered the Indonesian market and appeared on the local academic stage, and has also completed the first round of traditional Chinese medicine submission in Canada. Yulin Pharmaceutical's products also continue to focus on key Southeast Asian markets, implementing "one country, one policy" promotion. On the innovative R&D front, the company's pace is firm, with its R&D model evolving toward "source innovation." In the first half, CONSUN PHARMA's R&D investment was approximately RMB 90.823 million, a significant year-on-year increase. In terms of the pipeline under research, Qijian Granules, a Class 1.1 innovative Chinese medicine for treating diabetic nephropathy, officially obtained clinical trial approval from the National Medical Products Administration in August; another product, Baihua Zilian Granules, for treating lupus nephritis, is planned for IND submission in the second quarter of 2027. At the capital market level, CONSUN PHARMA has been included in the Stock Connect Southbound trading list since March 9, and multiple brokerages have given positive ratings. After the results, a research report by China Merchants Securities International believed that CONSUN PHARMA's interim results verified the steady growth of its nephrology foundation and its execution capability in transforming into an innovative drug platform, with valuation still at a relatively low level, giving an "Accumulate" rating with a target price of HK$22.6. Guoyuan International issued a research report stating that the company has strong product power, high technical and market barriers for Uremic Clearance Granules, and extremely difficult imitation, and the company's performance is expected to continue growing rapidly, giving a "Buy" rating with a target price of HK$19.16. Overall, CONSUN PHARMA has outlined a clear development blueprint: the core nephrology business provides a steady performance foundation and ample cash flow, diversified business segments contribute incremental elasticity, and the strategic layout of simultaneous advancement in industrial chain extension, overseas expansion, and innovative R&D makes the company's long-term value trend align with the current tone of Hong Kong pharmaceutical investment. At a time when market sentiment is warming and the sector trend reversal is established, the company's stock price is expected to usher in a "Davis double play," demonstrating considerable upward elasticity to the market.